Risk Factors for COVID-19 in Inflammatory Bowel Disease :: A National, ENEIDA-Based Case-Control Study (COVID-19-EII)

Yamile Zabana; Ignacio Marín-Jiménez; Iago Rodríguez-Lago; Isabel Vera; María Dolores Martín-Arranz; Iván Guerra; Javier P. Gisbert; Francisco Mesonero; Olga Benítez-Leiva; Carlos Taxonera; Ángel Ponferrada Díaz; Marta Piqueras; Alfredo J Lucendo; Berta Caballol; Míriam Mañosa i Ciria; Pilar Martínez-Montiel; Marta Maia Bosca-Watts; Jordi Gordillo; Luis Bujanda; Noemí Manceñido; Teresa Martínez-Pérez; Alicia López; Cristina Rodríguez-Gutiérrez; Santiago García-López; Pablo Vega; Montserrat Rivero; Luigi Melcarne; María Calvo Iñiguez; Marisa Iborra; Manuel Barreiro de-Acosta; Beatriz Sicilia; Jesús Barrio; José Lázaro Pérez Calle; David Busquets; Isabel Pérez-Martínez; Mercè Navarro-Llavat; Vicent Hernández; Federico Argüelles-Arias; Fernando Ramírez Esteso; Susana Meijide; Laura Ramos; Fernando Gomollón; Fernando Muñoz; Gerard Suris; Jone Ortiz de Zarate; José María Huguet; Jordina Llaó; Mariana Fe García-Sepulcre; Mónica Sierra Ausín; Miguel Durà; Sandra Estrecha; Ana María Fuentes Coronel; Esther Hinojosa; Lorenzo Olivan; Eva Iglesias; Ana Gutiérrez Casbas; Pilar Varela; Núria Rull; Pau Gilabert; Alejandro Hernández Camba; Alicia Brotons; Daniel Ginard; Eva Sesé; Daniel Carpio; Montserrat Aceituno; José Luis Cabriada; Yago González-Lama; Laura Jiménez; María Chaparro; Antonio López-San Román; Cristina Alba; Rocío Plaza-Santos; Raquel Mena; Sonsoles Tamarit-Sebastián; Elena Ricart; Margalida Calafat; Sonsoles Olivares; Pablo Navarro; Federico Bertoletti; Horacio Alonso-Galán; Ramón Pajares; Pablo Olcina; Pamela Manzano; Eugeni Domènech; Maria Esteve

doi:10.3390/jcm11247540

Risk Factors for COVID-19 in Inflammatory Bowel Disease : A National, ENEIDA-Based Case-Control Study (COVID-19-EII)

Yamile Zabana, Ignacio Marín-Jiménez, Iago Rodríguez-Lago, Isabel Vera, María Dolores Martín-Arranz, Iván Guerra, Javier P. Gisbert, Francisco Mesonero, Olga Benítez-Leiva, Carlos Taxonera, Ángel Ponferrada Díaz, Marta Piqueras, Alfredo J Lucendo, Berta Caballol, Míriam Mañosa i Ciria, Pilar Martínez-Montiel, Marta Maia Bosca-Watts, Jordi Gordillo, Luis Bujanda, Noemí ManceñidoTeresa Martínez-Pérez, Alicia López, Cristina Rodríguez-Gutiérrez, Santiago García-López, Pablo Vega, Montserrat Rivero, Luigi Melcarne , María Calvo Iñiguez, Marisa Iborra, Manuel Barreiro de-Acosta, Beatriz Sicilia, Jesús Barrio, José Lázaro Pérez Calle, David Busquets, Isabel Pérez-Martínez, Mercè Navarro-Llavat, Vicent Hernández, Federico Argüelles-Arias, Fernando Ramírez Esteso, Susana Meijide, Laura Ramos, Fernando Gomollón, Fernando Muñoz, Gerard Suris, Jone Ortiz de Zarate, José María Huguet, Jordina Llaó, Mariana Fe García-Sepulcre, Mónica Sierra Ausín, Miguel Durà, Sandra Estrecha, Ana María Fuentes Coronel, Esther Hinojosa, Lorenzo Olivan, Eva Iglesias, Ana Gutiérrez Casbas, Pilar Varela, Núria Rull, Pau Gilabert, Alejandro Hernández Camba, Alicia Brotons, Daniel Ginard, Eva Sesé, Daniel Carpio, Montserrat Aceituno, José Luis Cabriada, Yago González-Lama, Laura Jiménez, María Chaparro, Antonio López-San Román, Cristina Alba, Rocío Plaza-Santos, Raquel Mena, Sonsoles Tamarit-Sebastián, Elena Ricart, Margalida Calafat, Sonsoles Olivares, Pablo Navarro, Federico Bertoletti, Horacio Alonso-Galán, Ramón Pajares, Pablo Olcina, Pamela Manzano, Eugeni Domènech, Maria Esteve

Departament de Medicina

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

3 Cites (Scopus)

Resum

(1) Scant information is available concerning the characteristics that may favour the acquisition of COVID-19 in patients with inflammatory bowel disease (IBD). Therefore, the aim of this study was to assess these differences between infected and noninfected patients with IBD. (2) This nationwide case-control study evaluated patients with inflammatory bowel disease with COVID-19 (cases) and without COVID-19 (controls) during the period March-July 2020 included in the ENEIDA of GETECCU. (3) A total of 496 cases and 964 controls from 73 Spanish centres were included. No differences were found in the basal characteristics between cases and controls. Cases had higher comorbidity Charlson scores (24% vs. 19%; p = 0.02) and occupational risk (28% vs. 10.5%; p < 0.0001) more frequently than did controls. Lockdown was the only protective measure against COVID-19 (50% vs. 70%; p < 0.0001). No differences were found in the use of systemic steroids, immunosuppressants or biologics between cases and controls. Cases were more often treated with 5-aminosalicylates (42% vs. 34%; p = 0.003). Having a moderate Charlson score (OR: 2.7; 95%CI: 1.3-5.9), occupational risk (OR: 2.9; 95%CI: 1.8-4.4) and the use of 5-aminosalicylates (OR: 1.7; 95%CI: 1.2-2.5) were factors for COVID-19. The strict lockdown was the only protective factor (OR: 0.1; 95%CI: 0.09-0.2). (4) Comorbidities and occupational exposure are the most relevant factors for COVID-19 in patients with IBD. The risk of COVID-19 seems not to be increased by immunosuppressants or biologics, with a potential effect of 5-aminosalicylates, which should be investigated further and interpreted with caution.

Idioma original	Anglès
Revista	Journal of Clinical Medicine
Volum	11
DOIs	https://doi.org/10.3390/jcm11247540
Estat de la publicació	Publicada - 2022

Accés al document

10.3390/jcm11247540

https://ddd.uab.cat/record/281720

Com citar-ho

Zabana, Y., Marín-Jiménez, I., Rodríguez-Lago, I., Vera, I., Martín-Arranz, M. D., Guerra, I., P. Gisbert, J., Mesonero, F., Benítez-Leiva, O., Taxonera, C., Ponferrada Díaz, Á., Piqueras, M., Lucendo, A. J., Caballol, B., Mañosa i Ciria, M., Martínez-Montiel, P., Bosca-Watts, M. M., Gordillo, J., Bujanda, L., ... Esteve, M. (2022). Risk Factors for COVID-19 in Inflammatory Bowel Disease : A National, ENEIDA-Based Case-Control Study (COVID-19-EII). Journal of Clinical Medicine, 11. https://doi.org/10.3390/jcm11247540

@article{661906e492244846a43b7ec604169f5e,

title = "Risk Factors for COVID-19 in Inflammatory Bowel Disease :: A National, ENEIDA-Based Case-Control Study (COVID-19-EII)",

abstract = "(1) Scant information is available concerning the characteristics that may favour the acquisition of COVID-19 in patients with inflammatory bowel disease (IBD). Therefore, the aim of this study was to assess these differences between infected and noninfected patients with IBD. (2) This nationwide case-control study evaluated patients with inflammatory bowel disease with COVID-19 (cases) and without COVID-19 (controls) during the period March-July 2020 included in the ENEIDA of GETECCU. (3) A total of 496 cases and 964 controls from 73 Spanish centres were included. No differences were found in the basal characteristics between cases and controls. Cases had higher comorbidity Charlson scores (24% vs. 19%; p = 0.02) and occupational risk (28% vs. 10.5%; p < 0.0001) more frequently than did controls. Lockdown was the only protective measure against COVID-19 (50% vs. 70%; p < 0.0001). No differences were found in the use of systemic steroids, immunosuppressants or biologics between cases and controls. Cases were more often treated with 5-aminosalicylates (42% vs. 34%; p = 0.003). Having a moderate Charlson score (OR: 2.7; 95%CI: 1.3-5.9), occupational risk (OR: 2.9; 95%CI: 1.8-4.4) and the use of 5-aminosalicylates (OR: 1.7; 95%CI: 1.2-2.5) were factors for COVID-19. The strict lockdown was the only protective factor (OR: 0.1; 95%CI: 0.09-0.2). (4) Comorbidities and occupational exposure are the most relevant factors for COVID-19 in patients with IBD. The risk of COVID-19 seems not to be increased by immunosuppressants or biologics, with a potential effect of 5-aminosalicylates, which should be investigated further and interpreted with caution.",

keywords = "COVID-19, SARS-CoV-2, Inflammatory bowel disease, 5-aminosalicylates, Immunosuppression",

author = "Yamile Zabana and Ignacio Mar{\'i}n-Jim{\'e}nez and Iago Rodr{\'i}guez-Lago and Isabel Vera and Mart{\'i}n-Arranz, {Mar{\'i}a Dolores} and Iv{\'a}n Guerra and {P. Gisbert}, Javier and Francisco Mesonero and Olga Ben{\'i}tez-Leiva and Carlos Taxonera and {Ponferrada D{\'i}az}, {\'A}ngel and Marta Piqueras and Lucendo, {Alfredo J} and Berta Caballol and {Ma{\~n}osa i Ciria}, M{\'i}riam and Pilar Mart{\'i}nez-Montiel and Bosca-Watts, {Marta Maia} and Jordi Gordillo and Luis Bujanda and Noem{\'i} Mance{\~n}ido and Teresa Mart{\'i}nez-P{\'e}rez and Alicia L{\'o}pez and Cristina Rodr{\'i}guez-Guti{\'e}rrez and Santiago Garc{\'i}a-L{\'o}pez and Pablo Vega and Montserrat Rivero and Luigi Melcarne and {Calvo I{\~n}iguez}, Mar{\'i}a and Marisa Iborra and {Barreiro de-Acosta}, Manuel and Beatriz Sicilia and Jes{\'u}s Barrio and {P{\'e}rez Calle}, {Jos{\'e} L{\'a}zaro} and David Busquets and Isabel P{\'e}rez-Mart{\'i}nez and Merc{\`e} Navarro-Llavat and Vicent Hern{\'a}ndez and Federico Arg{\"u}elles-Arias and {Ram{\'i}rez Esteso}, Fernando and Susana Meijide and Laura Ramos and Fernando Gomoll{\'o}n and Fernando Mu{\~n}oz and Gerard Suris and {Ortiz de Zarate}, Jone and Huguet, {Jos{\'e} Mar{\'i}a} and Jordina Lla{\'o} and Garc{\'i}a-Sepulcre, {Mariana Fe} and {Sierra Aus{\'i}n}, M{\'o}nica and Miguel Dur{\`a} and Sandra Estrecha and {Fuentes Coronel}, {Ana Mar{\'i}a} and Esther Hinojosa and Lorenzo Olivan and Eva Iglesias and {Guti{\'e}rrez Casbas}, Ana and Pilar Varela and N{\'u}ria Rull and Pau Gilabert and {Hern{\'a}ndez Camba}, Alejandro and Alicia Brotons and Daniel Ginard and Eva Ses{\'e} and Daniel Carpio and Montserrat Aceituno and Cabriada, {Jos{\'e} Luis} and Yago Gonz{\'a}lez-Lama and Laura Jim{\'e}nez and Mar{\'i}a Chaparro and {L{\'o}pez-San Rom{\'a}n}, Antonio and Cristina Alba and Roc{\'i}o Plaza-Santos and Raquel Mena and Sonsoles Tamarit-Sebasti{\'a}n and Elena Ricart and Margalida Calafat and Sonsoles Olivares and Pablo Navarro and Federico Bertoletti and Horacio Alonso-Gal{\'a}n and Ram{\'o}n Pajares and Pablo Olcina and Pamela Manzano and Eugeni Dom{\`e}nech and Maria Esteve",

year = "2022",

doi = "10.3390/jcm11247540",

language = "English",

volume = "11",

}

Zabana, Y, Marín-Jiménez, I, Rodríguez-Lago, I, Vera, I, Martín-Arranz, MD, Guerra, I, P. Gisbert, J, Mesonero, F, Benítez-Leiva, O, Taxonera, C, Ponferrada Díaz, Á, Piqueras, M, Lucendo, AJ, Caballol, B, Mañosa i Ciria, M, Martínez-Montiel, P, Bosca-Watts, MM, Gordillo, J, Bujanda, L, Manceñido, N, Martínez-Pérez, T, López, A, Rodríguez-Gutiérrez, C, García-López, S, Vega, P, Rivero, M, Melcarne , L, Calvo Iñiguez, M, Iborra, M, Barreiro de-Acosta, M, Sicilia, B, Barrio, J, Pérez Calle, JL, Busquets, D, Pérez-Martínez, I, Navarro-Llavat, M, Hernández, V, Argüelles-Arias, F, Ramírez Esteso, F, Meijide, S, Ramos, L, Gomollón, F, Muñoz, F, Suris, G, Ortiz de Zarate, J, Huguet, JM, Llaó, J, García-Sepulcre, MF, Sierra Ausín, M, Durà, M, Estrecha, S, Fuentes Coronel, AM, Hinojosa, E, Olivan, L, Iglesias, E, Gutiérrez Casbas, A, Varela, P, Rull, N, Gilabert, P, Hernández Camba, A, Brotons, A, Ginard, D, Sesé, E, Carpio, D, Aceituno, M, Cabriada, JL, González-Lama, Y, Jiménez, L, Chaparro, M, López-San Román, A, Alba, C, Plaza-Santos, R, Mena, R, Tamarit-Sebastián, S, Ricart, E, Calafat, M, Olivares, S, Navarro, P, Bertoletti, F, Alonso-Galán, H, Pajares, R, Olcina, P, Manzano, P, Domènech, E & Esteve, M 2022, 'Risk Factors for COVID-19 in Inflammatory Bowel Disease : A National, ENEIDA-Based Case-Control Study (COVID-19-EII)', Journal of Clinical Medicine, vol. 11. https://doi.org/10.3390/jcm11247540

TY - JOUR

T1 - Risk Factors for COVID-19 in Inflammatory Bowel Disease :

T2 - A National, ENEIDA-Based Case-Control Study (COVID-19-EII)

AU - Zabana, Yamile

AU - Marín-Jiménez, Ignacio

AU - Rodríguez-Lago, Iago

AU - Vera, Isabel

AU - Martín-Arranz, María Dolores

AU - Guerra, Iván

AU - P. Gisbert, Javier

AU - Mesonero, Francisco

AU - Benítez-Leiva, Olga

AU - Taxonera, Carlos

AU - Ponferrada Díaz, Ángel

AU - Piqueras, Marta

AU - Lucendo, Alfredo J

AU - Caballol, Berta

AU - Mañosa i Ciria, Míriam

AU - Martínez-Montiel, Pilar

AU - Bosca-Watts, Marta Maia

AU - Gordillo, Jordi

AU - Bujanda, Luis

AU - Manceñido, Noemí

AU - Martínez-Pérez, Teresa

AU - López, Alicia

AU - Rodríguez-Gutiérrez, Cristina

AU - García-López, Santiago

AU - Vega, Pablo

AU - Rivero, Montserrat

AU - Melcarne , Luigi

AU - Calvo Iñiguez, María

AU - Iborra, Marisa

AU - Barreiro de-Acosta, Manuel

AU - Sicilia, Beatriz

AU - Barrio, Jesús

AU - Pérez Calle, José Lázaro

AU - Busquets, David

AU - Pérez-Martínez, Isabel

AU - Navarro-Llavat, Mercè

AU - Hernández, Vicent

AU - Argüelles-Arias, Federico

AU - Ramírez Esteso, Fernando

AU - Meijide, Susana

AU - Ramos, Laura

AU - Gomollón, Fernando

AU - Muñoz, Fernando

AU - Suris, Gerard

AU - Ortiz de Zarate, Jone

AU - Huguet, José María

AU - Llaó, Jordina

AU - García-Sepulcre, Mariana Fe

AU - Sierra Ausín, Mónica

AU - Durà, Miguel

AU - Estrecha, Sandra

AU - Fuentes Coronel, Ana María

AU - Hinojosa, Esther

AU - Olivan, Lorenzo

AU - Iglesias, Eva

AU - Gutiérrez Casbas, Ana

AU - Varela, Pilar

AU - Rull, Núria

AU - Gilabert, Pau

AU - Hernández Camba, Alejandro

AU - Brotons, Alicia

AU - Ginard, Daniel

AU - Sesé, Eva

AU - Carpio, Daniel

AU - Aceituno, Montserrat

AU - Cabriada, José Luis

AU - González-Lama, Yago

AU - Jiménez, Laura

AU - Chaparro, María

AU - López-San Román, Antonio

AU - Alba, Cristina

AU - Plaza-Santos, Rocío

AU - Mena, Raquel

AU - Tamarit-Sebastián, Sonsoles

AU - Ricart, Elena

AU - Calafat, Margalida

AU - Olivares, Sonsoles

AU - Navarro, Pablo

AU - Bertoletti, Federico

AU - Alonso-Galán, Horacio

AU - Pajares, Ramón

AU - Olcina, Pablo

AU - Manzano, Pamela

AU - Domènech, Eugeni

AU - Esteve, Maria

PY - 2022

Y1 - 2022

N2 - (1) Scant information is available concerning the characteristics that may favour the acquisition of COVID-19 in patients with inflammatory bowel disease (IBD). Therefore, the aim of this study was to assess these differences between infected and noninfected patients with IBD. (2) This nationwide case-control study evaluated patients with inflammatory bowel disease with COVID-19 (cases) and without COVID-19 (controls) during the period March-July 2020 included in the ENEIDA of GETECCU. (3) A total of 496 cases and 964 controls from 73 Spanish centres were included. No differences were found in the basal characteristics between cases and controls. Cases had higher comorbidity Charlson scores (24% vs. 19%; p = 0.02) and occupational risk (28% vs. 10.5%; p < 0.0001) more frequently than did controls. Lockdown was the only protective measure against COVID-19 (50% vs. 70%; p < 0.0001). No differences were found in the use of systemic steroids, immunosuppressants or biologics between cases and controls. Cases were more often treated with 5-aminosalicylates (42% vs. 34%; p = 0.003). Having a moderate Charlson score (OR: 2.7; 95%CI: 1.3-5.9), occupational risk (OR: 2.9; 95%CI: 1.8-4.4) and the use of 5-aminosalicylates (OR: 1.7; 95%CI: 1.2-2.5) were factors for COVID-19. The strict lockdown was the only protective factor (OR: 0.1; 95%CI: 0.09-0.2). (4) Comorbidities and occupational exposure are the most relevant factors for COVID-19 in patients with IBD. The risk of COVID-19 seems not to be increased by immunosuppressants or biologics, with a potential effect of 5-aminosalicylates, which should be investigated further and interpreted with caution.

AB - (1) Scant information is available concerning the characteristics that may favour the acquisition of COVID-19 in patients with inflammatory bowel disease (IBD). Therefore, the aim of this study was to assess these differences between infected and noninfected patients with IBD. (2) This nationwide case-control study evaluated patients with inflammatory bowel disease with COVID-19 (cases) and without COVID-19 (controls) during the period March-July 2020 included in the ENEIDA of GETECCU. (3) A total of 496 cases and 964 controls from 73 Spanish centres were included. No differences were found in the basal characteristics between cases and controls. Cases had higher comorbidity Charlson scores (24% vs. 19%; p = 0.02) and occupational risk (28% vs. 10.5%; p < 0.0001) more frequently than did controls. Lockdown was the only protective measure against COVID-19 (50% vs. 70%; p < 0.0001). No differences were found in the use of systemic steroids, immunosuppressants or biologics between cases and controls. Cases were more often treated with 5-aminosalicylates (42% vs. 34%; p = 0.003). Having a moderate Charlson score (OR: 2.7; 95%CI: 1.3-5.9), occupational risk (OR: 2.9; 95%CI: 1.8-4.4) and the use of 5-aminosalicylates (OR: 1.7; 95%CI: 1.2-2.5) were factors for COVID-19. The strict lockdown was the only protective factor (OR: 0.1; 95%CI: 0.09-0.2). (4) Comorbidities and occupational exposure are the most relevant factors for COVID-19 in patients with IBD. The risk of COVID-19 seems not to be increased by immunosuppressants or biologics, with a potential effect of 5-aminosalicylates, which should be investigated further and interpreted with caution.

KW - COVID-19

KW - SARS-CoV-2

KW - Inflammatory bowel disease

KW - 5-aminosalicylates

KW - Immunosuppression

U2 - 10.3390/jcm11247540

DO - 10.3390/jcm11247540

M3 - Article

C2 - 36556155

SN - 2077-0383

VL - 11

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

ER -

Risk Factors for COVID-19 in Inflammatory Bowel Disease : A National, ENEIDA-Based Case-Control Study (COVID-19-EII)

Resum

Accés al document

Fingerprint

Com citar-ho